A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World.
NCT01955681 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2015-11-04
Summary
This is a retrospective, non-interventional, multicenter, observational chart review study to explore the clinical benefits of retreatment with TKI in the real world.
Conditions
- Locally Advanced or Metastatic EGFR Mutated NSCLC.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Yuh-Min Chen · Taipei Veterans General Hospital, Taiwan
-
Gee-Chen Chang · Veterans General Hospital -Taichung
-
Chong-Jen Yu · National Taiwan University Hospital
-
Cheng-Ta Yang · Chang Gung Memorial Hospital
-
Te-Chun Hsia · China Medical University Hospital
-
Meng-Chih Lin · Chang-Gung Memorial Hospital Kaohsiung
-
Ying-Huang Tsai · Chang Gung Memorial Hospital, Chiayi
Eligibility
- Min Age
- 20 Years
- Max Age
- 150 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-12-31
- Primary Completion
- 2014-08-31
- Completion
- 2014-08-31
Countries
- Taiwan
Study Locations
More Related Trials
-
Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy
NCT00836160 ·Status: COMPLETED
-
EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC
NCT02988141 ·Status: UNKNOWN
-
De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
NCT01697163 ·Status: UNKNOWN
-
Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor
NCT01947868 ·Status: COMPLETED
-
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
NCT01994057 ·Status: RECRUITING
-
Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC
NCT02250846 ·Status: UNKNOWN ·Phase: PHASE2
-
Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
NCT02474355 ·Status: COMPLETED ·Phase: PHASE3
-
EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC
NCT02886195 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation
NCT05146219 ·Status: COMPLETED ·Phase: PHASE2
-
Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer
NCT02228369 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours
NCT02094261 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy
NCT02788058 ·Status: UNKNOWN ·Phase: PHASE2
-
TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC
NCT03916913 ·Status: UNKNOWN ·Phase: NA
-
Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS
NCT03257124 ·Status: UNKNOWN ·Phase: PHASE2
-
EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression
NCT03544814 ·Status: COMPLETED ·Phase: PHASE2
-
Primary Tumor Resection With EGFR TKI for Stage IV NSCLC
NCT05215548 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
NCT04324164 ·Status: RECRUITING
-
Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.
NCT07213076 ·Status: COMPLETED
-
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
NCT06071013 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)
NCT02293733 ·Status: COMPLETED
-
Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations
NCT04811001 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
NCT03219970 ·Status: COMPLETED
-
Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)
NCT02475720 ·Status: COMPLETED
-
Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma
NCT04974866 ·Status: RECRUITING ·Phase: PHASE2
-
Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC
NCT03133234 ·Status: COMPLETED